The ASCT parameters in the PPM1D-mutated (PPM1Dmut) vs. PPM1D wild-type (PPM1Dwt) subset of myeloma patients were comparable, with normal stem cell mobilization and stem cell yields before ASCT, but there was a larger amount of platelet transfusions required in patients with PPM1D gene mutations, indicating impaired regeneration in these ASCT recipients. Here, PPM1D is linked to plasma cell myeloma.